S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Laser breakthrough could send stock soaring 2,467% (Ad)
How major US stock indexes fared Friday, 2/23/2024
MarketBeat Week in Review – 2/19 - 2/23
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Closing prices for crude oil, gold and other commodities
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
Mike Tyson’s Wisdom: Life, Planning, and Resilience
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Laser breakthrough could send stock soaring 2,467% (Ad)
How major US stock indexes fared Friday, 2/23/2024
MarketBeat Week in Review – 2/19 - 2/23
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Closing prices for crude oil, gold and other commodities
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
Mike Tyson’s Wisdom: Life, Planning, and Resilience
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Laser breakthrough could send stock soaring 2,467% (Ad)
How major US stock indexes fared Friday, 2/23/2024
MarketBeat Week in Review – 2/19 - 2/23
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Closing prices for crude oil, gold and other commodities
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
Mike Tyson’s Wisdom: Life, Planning, and Resilience
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Laser breakthrough could send stock soaring 2,467% (Ad)
How major US stock indexes fared Friday, 2/23/2024
MarketBeat Week in Review – 2/19 - 2/23
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Closing prices for crude oil, gold and other commodities
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
Mike Tyson’s Wisdom: Life, Planning, and Resilience
NASDAQ:EFTRW

eFFECTOR Therapeutics (EFTRW) Stock Price, News & Analysis

$0.14
+0.01 (+7.69%)
(As of 02/23/2024 ET)
Today's Range
$0.13
$0.15
50-Day Range
$0.07
$0.16
52-Week Range
$0.06
$0.21
Volume
19,452 shs
Average Volume
13,615 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

EFTRW stock logo

About eFFECTOR Therapeutics Stock (NASDAQ:EFTRW)

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics, Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

EFTRW Stock Price History

EFTRW Stock News Headlines

eFFECTOR Therapeutics Inc. Warrant
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
eFFECTOR Therapeutics Announces Reverse Stock Split
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
eFFECTOR Therapeutics Inc.
See More Headlines
Receive EFTRW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for eFFECTOR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:EFTRW
Fax
N/A
Employees
15
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Stephen T. Worland Ph.D. (Age 66)
    CEO, President & Director
    Comp: $855.25k
  • Mr. Michael Byrnes M.B.A. (Age 47)
    Chief Financial Officer
    Comp: $623.69k
  • Dr. Douglas Warner M.D. (Age 52)
    Chief Medical Officer
    Comp: $304.4k
  • Dr. Davide Ruggero Ph.D.
    Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Kevan M. Shokat Ph.D.
    Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Mayank J. Gandhi M.D. (Age 46)
    Chief Business Officer














EFTRW Stock Analysis - Frequently Asked Questions

How have EFTRW shares performed in 2024?

eFFECTOR Therapeutics' stock was trading at $0.1475 at the beginning of 2024. Since then, EFTRW shares have decreased by 5.1% and is now trading at $0.14.
View the best growth stocks for 2024 here
.

Are investors shorting eFFECTOR Therapeutics?

eFFECTOR Therapeutics saw a decrease in short interest in January. As of January 31st, there was short interest totaling 1,900 shares, a decrease of 9.5% from the January 15th total of 2,100 shares. Based on an average daily volume of 5,700 shares, the days-to-cover ratio is currently 0.3 days.
View eFFECTOR Therapeutics' Short Interest
.

Who are eFFECTOR Therapeutics' major shareholders?

eFFECTOR Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of eFFECTOR Therapeutics?

Shares of EFTRW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EFTRW) was last updated on 2/24/2024 by MarketBeat.com Staff